Flamel Technologies (AVDL) and Acura Pharmaceuticals (NASDAQ:ACUR) Critical Survey

Flamel Technologies (NASDAQ: AVDL) and Acura Pharmaceuticals (NASDAQ:ACUR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitabiliy and earnings.

Volatility & Risk

Flamel Technologies has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Acura Pharmaceuticals has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500.

Valuation & Earnings

This table compares Flamel Technologies and Acura Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
Flamel Technologies	$166.54 million	2.46	$58.40 million	($0.32)	-30.91
Acura Pharmaceuticals	$6.96 million	N/A	-$2.50 million	($0.83)	-0.63

Flamel Technologies has higher revenue and earnings than Acura Pharmaceuticals. Flamel Technologies is trading at a lower price-to-earnings ratio than Acura Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Flamel Technologies and Acura Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Flamel Technologies	-7.28%	14.49%	2.74%
Acura Pharmaceuticals	14.91%	112.19%	19.04%

Insider & Institutional Ownership

70.4% of Flamel Technologies shares are held by institutional investors. Comparatively, 31.2% of Acura Pharmaceuticals shares are held by institutional investors. 5.1% of Flamel Technologies shares are held by insiders. Comparatively, 7.4% of Acura Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Flamel Technologies and Acura Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flamel Technologies	0	0	2	0	3.00
Acura Pharmaceuticals	0	0	2	0	3.00

Flamel Technologies presently has a consensus target price of $16.00, suggesting a potential upside of 61.78%. Acura Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 1,438.46%. Given Acura Pharmaceuticals’ higher probable upside, analysts clearly believe Acura Pharmaceuticals is more favorable than Flamel Technologies.

Summary

Acura Pharmaceuticals beats Flamel Technologies on 6 of the 10 factors compared between the two stocks.

Flamel Technologies Company Profile

Flamel Technologies S.A. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms. The Company owns and develops drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company has two direct operating subsidiaries: Flamel US Holdings, Inc. and Flamel Irish Holdings, Ltd.

Acura Pharmaceuticals Company Profile

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.